February 13, 2019
FDA warns of link between breast implants and anaplastic large cell lymphoma
Editor's Note
The Food and Drug Administration (FDA) on February 6 posted a letter that was sent to healthcare providers to increase their awareness of the association between all breast implants, regardless of filling or texture, and breast implant associated-anaplastic large cell lymphoma (BIA-ALCL).
As of September 30, 2018, the FDA has received 660 medical device reports of patients who have developed BIA-ALCL, generally within the scar capsule adjacent to the implant.
Free Daily News
- Share your expertise! Topics, speakers sought for 2025 ORBMC
- FDA approves imaging drug for detecting cancer after lumpectomy
- Penn Medicine anesthesia, waste initiatives boost OR sustainability
- Survey assesses continued impact of Change Healthcare cyberattack
- WHO sounds alarm on potential spread of bird flu
- Allison Massari to deliver hopeful, empowering keynote address at OR Manager Conference 2024
- Neurosurgery trial: Early evacuation improves long-term hemorrhage outcomes
- Drug shortages higher than ever
- FDA announces class 1 recalls for premixed embolic, infusion pump software
- Academic medical centers identify performance-improvement priorities
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging